- Home
- AGIO vs NN Comparison
AGIO vs NN Comparison
Compare AGIO & NN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- NN
- Stock Information
- Founded
- AGIO 2007
- NN 2007
- Country
- AGIO United States
- NN United States
- Employees
- AGIO N/A
- NN N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- NN Industrial Machinery/Components
- Sector
- AGIO Health Care
- NN Industrials
- Exchange
- AGIO Nasdaq
- NN Nasdaq
- Market Cap
- AGIO 1.4B
- NN 1.5B
- IPO Year
- AGIO 2013
- NN N/A
- Fundamental
- Price
- AGIO $27.32
- NN $13.12
- Analyst Decision
- AGIO Buy
- NN
- Analyst Count
- AGIO 8
- NN 0
- Target Price
- AGIO $56.00
- NN N/A
- AVG Volume (30 Days)
- AGIO 524.5K
- NN 959.8K
- Earning Date
- AGIO 05-01-2025
- NN 05-09-2025
- Dividend Yield
- AGIO N/A
- NN N/A
- EPS Growth
- AGIO N/A
- NN N/A
- EPS
- AGIO 11.45
- NN N/A
- Revenue
- AGIO $37,035,000.00
- NN $6,162,000.00
- Revenue This Year
- AGIO $40.62
- NN $42.99
- Revenue Next Year
- AGIO $216.26
- NN $122.93
- P/E Ratio
- AGIO $2.39
- NN N/A
- Revenue Growth
- AGIO 25.96
- NN 51.10
- 52 Week Low
- AGIO $23.42
- NN $6.47
- 52 Week High
- AGIO $62.58
- NN $18.54
- Technical
- Relative Strength Index (RSI)
- AGIO 41.34
- NN 56.02
- Support Level
- AGIO $27.78
- NN $12.44
- Resistance Level
- AGIO $31.55
- NN $13.60
- Average True Range (ATR)
- AGIO 1.38
- NN 0.76
- MACD
- AGIO -0.03
- NN 0.16
- Stochastic Oscillator
- AGIO 2.98
- NN 63.79
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.